Takeda Pharmaceutical Co Ltd (NYSE:TAK)
$ 15.91 +0.26 (+1.66%) Market Cap: 50.27 Bil Enterprise Value: 76.83 Bil PE Ratio: 0 PB Ratio: 1.08 GF Score: 76/100

Q2 2026 Takeda Pharmaceutical Co Ltd Earnings Presentation Transcript

Oct 30, 2025 / 10:00AM GMT
Release Date Price: $13.23 (-3.92%)

Oct 30, 2025 / 10:00AM GMT
Presentation
Oct 30, 2025 / 10:00AM GMT

=====================
Corporate Participants
=====================
* Christopher O'Reilly
Takeda Pharmaceutical Co Ltd - Global Head of Investor Relations
* Christophe Weber
Takeda Pharmaceutical Co Ltd - President, Chief Executive Officer, Representative Director
* Milano Furuta
Takeda Pharmaceutical Co Ltd - Chief Financial Officer, Director
* Andrew Plump
Takeda Pharmaceutical Co Ltd - President of Research & Development, Vice President of Subsidiary, Director
* Teresa Bitetti
Takeda Pharmaceutical Co Ltd - President, Global Oncology, Takeda
* Phuong Morrow
Takeda Pharmaceutical Co Ltd - Head, Oncology Therapeutic Area Unit
* Julie Kim
Takeda Pharmaceutical Co Ltd - President of the US Business Unit, US Country Head & Interim Head of Global Portfolio Division
* Giles Platford
Takeda Pharmaceutical Co Ltd - President, Plasma-Derived Therapies Business

=====================
Conference Call Participants
============

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot